CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,273 enrolled
Drug / intervention
Gabapentindrug
Likely dose
Gabapentin 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00567268
NCT00567268N/ACompleted

Drug Use Investigation Of Gabapen

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Dec 4, 2007·Updated Feb 3, 2021

In Brief

An observational study evaluating Gabapentin for Epilepsies, Partial. Completed, enrolled 1,273 participants.

Detailed Summary

The objective of the this surveillance is to collect information about 1)adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 4, 2007
Enrollment StartAug 1, 2007
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 18.6 years ago

Interventions

Gabapentindrug

GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan. Dosage, frequency: According to Japanese LPD, "Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg)". Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration.